<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03557892</url>
  </required_header>
  <id_info>
    <org_study_id>T1DM001</org_study_id>
    <nct_id>NCT03557892</nct_id>
  </id_info>
  <brief_title>Sensor-augmented Pump Versus Multiple Daily Injections With Degludec as Basal Insulin for Insulin Therapy in Type 1 Diabetes</brief_title>
  <official_title>Continuous Subcutaneous Insulin Infusion Associated With Continuous Glucose Monitoring in Comparison With Subcutaneous Multi-injection Insulin Therapy Using Degludec as Basal Insulin: a Randomized Crossover Trial in Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero-Universitaria Careggi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliero-Universitaria Careggi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several studies have shown that Continuous Subcutaneous Insulin Infusion together with
      Continuous Glucose Monitoring improves glycemic control in type 1 diabetes when compared to
      more traditional approaches; however, in available trials the basal insulin used in
      multi-injection therapy is typically glargine, which is associated with a higher hypoglycemic
      risk than degludec.

      This study will assess the efficacy and safety of Continuous Subcutaneous Insulin infusion
      (CSII) combined with Continuous Glucose Monitoring (CGM), as compared to Multiple Daily
      Injections (MDI) of insulin analogues, using degludec as basal insulin, associated with
      traditional self-monitoring of capillary blood glucose (SMBG) in patients with type 1
      diabetes. A crossover design was chosen in order to minimize study sample improving
      statistical power.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Actual">January 2, 2020</completion_date>
  <primary_completion_date type="Actual">December 20, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>4 months</time_frame>
    <description>Variation of HbA1c in each treatment phase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severe hypoglycemia</measure>
    <time_frame>4 months</time_frame>
    <description>Incidence of severe hypoglycemia in each treatment phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>4 months</time_frame>
    <description>Weight change in each treatment phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local reactions</measure>
    <time_frame>4 months</time_frame>
    <description>Local reactions at infusion/glucose monitoring site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>World Health Organization Diabetes Treatment Satisfaction Questionnaire</measure>
    <time_frame>4 months</time_frame>
    <description>8-item questionnaire, each rated on a seven-point Likert scale; six (items 1 and 4-8) are summed to produce a measure of treatment satisfaction with scores ranging from 0 (very dissatisfied) to 36 (very satisfied). The remaining two items are treated individually. Item 2 measures perceived frequency of hyperglycemia on a scale ranging from 0 (none of the time) to 6 (most of the time), and item 3 measures perceived frequency of hypoglycemia on the same scale.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>CSII+CGM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MDI with degludec</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CGM+CSII</intervention_name>
    <description>Animas Vibe Platinum insulin pump and Dexcom G4 CGM</description>
    <arm_group_label>CSII+CGM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MDI with degludec</intervention_name>
    <description>Multiple injection therapy with any short-acting analogue as bolus insulin and degludec as basal insulin</description>
    <arm_group_label>MDI with degludec</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes

          -  Duration of diabetes &gt; 2 years

          -  Current treatment with MDI, using insulin analogues as bolus and basal insulin

          -  HbA1c&lt;64 mmol/mol

        Exclusion Criteria:

          -  HbA1c&gt;64 mmol/mol

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Diabetologia AOU Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 5, 2018</study_first_submitted>
  <study_first_submitted_qc>June 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2018</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero-Universitaria Careggi</investigator_affiliation>
    <investigator_full_name>Edoardo Mannucci</investigator_full_name>
    <investigator_title>Director, Diabetology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

